1-13 of 13
David R. Spriggs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR07: Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer

Yao Sun, Wenjianlong Zhao, David R. Spriggs, Rakesh K. Jain, Lei Xu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR07.
https://doi.org/10.1158/1557-3265.OVCA19-PR07
Published: 01 July 2020
View article titled, Abstract PR07: Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer
Journal Articles

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen A. Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, William P. Tew, Jason A. Konner, Martee L. Hensley, Vicky Makker, Paul Sabbatini, David R. Spriggs, Tiffany A. Troso-Sandoval, Alexandra Snyder Charen, Claire Friedman, Mila Gorsky, Sarah J. Schweber, Sumit Middha, Rajmohan Murali, Sarah Chiang, Kay J. Park, Robert A. Soslow, Marc Ladanyi, Bob T. Li, Jennifer Mueller, Britta Weigelt, Ahmet Zehir, Michael F. Berger, Nadeem R. Abu-Rustum, Carol Aghajanian, Deborah F. DeLair, David B. Solit, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5939–5947.
https://doi.org/10.1158/1078-0432.CCR-18-0412
Published: 03 December 2018
View article titled, Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Open the PDF for Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Measuring Toxicity in Phase I Clinical Trials—Letter

David M. Hyman, Anne Eaton, S. Percy Ivy, David R. Spriggs, Alexia Iasonos
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1828.
https://doi.org/10.1158/1078-0432.CCR-15-3043
Published: 31 March 2016
View article titled, Measuring Toxicity in Phase I Clinical Trials—Letter
Open the PDF for Measuring Toxicity in Phase I Clinical Trials—Letter in another window
Journal Articles

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

Anne Eaton, Alexia Iasonos, Mrinal M. Gounder, Erika G. Pamer, Alexander Drilon, Diana Vulih, Gary L. Smith, S. Percy Ivy, David R. Spriggs, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 553–559.
https://doi.org/10.1158/1078-0432.CCR-15-0339
Published: 31 January 2016
View article titled, Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Open the PDF for Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities in another window
Includes: Supplementary data
Journal Articles

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Lesley Seymour, Susan Groshen, Gary L. Rosner, Daniel M. Sullivan, David R. Spriggs, Steven Reeves, Amy Gravell, S. Percy Ivy, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5057–5063.
https://doi.org/10.1158/1078-0432.CCR-15-0035
Published: 12 November 2015
View article titled, Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Open the PDF for Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee in another window
Journal Articles

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Paul Sabbatini, Takemasa Tsuji, Luis Ferran, Erika Ritter, Christine Sedrak, Kevin Tuballes, Achim A. Jungbluth, Gerd Ritter, Carol Aghajanian, Katherine Bell-McGuinn, Martee L. Hensley, Jason Konner, William Tew, David R. Spriggs, Eric W. Hoffman, Ralph Venhaus, Linda Pan, Andres M. Salazar, Catherine Magid Diefenbach, Lloyd J. Old, Sacha Gnjatic
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6497–6508.
https://doi.org/10.1158/1078-0432.CCR-12-2189
Published: 29 November 2012
View article titled, Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Open the PDF for Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients in another window
Includes: Supplementary data
Journal Articles

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Alexia Iasonos, Mrinal Gounder, David R. Spriggs, John F. Gerecitano, David M. Hyman, Sarah Zohar, John O'Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5179–5187.
https://doi.org/10.1158/1078-0432.CCR-12-0726
Published: 30 September 2012
View article titled, The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
Open the PDF for The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials in another window
Includes: Supplementary data
Journal Articles

Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need

Mrinal M. Gounder, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 3855–3857.
https://doi.org/10.1158/1078-0432.CCR-11-0759
Published: 15 June 2011
View article titled, Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need
Open the PDF for Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need in another window
Includes: Supplementary data
Journal Articles

Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen

Alena A. Chekmasova, Thapi D. Rao, Yan Nikhamin, Kay J. Park, Douglas A. Levine, David R. Spriggs, Renier J. Brentjens
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3594–3606.
https://doi.org/10.1158/1078-0432.CCR-10-0192
Published: 14 July 2010
View article titled, Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
Open the PDF for Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen in another window
Includes: Supplementary data
Journal Articles

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

William P. Tew, Michael Gordon, John Murren, Jakob Dupont, Sandra Pezzulli, Carol Aghajanian, Paul Sabbatini, David Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 358–366.
https://doi.org/10.1158/1078-0432.CCR-09-2103
Published: 04 January 2010
View article titled, Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
Open the PDF for Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors in another window
Journal Articles

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

Catherine S.M. Diefenbach, Sacha Gnjatic, Paul Sabbatini, Carol Aghajanian, Martee L. Hensley, David R. Spriggs, Alexia Iasonos, Helen Lee, Bo Dupont, Sandra Pezzulli, Achim A. Jungbluth, Lloyd J. Old, Jakob Dupont
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2740–2748.
https://doi.org/10.1158/1078-0432.CCR-07-4619
Published: 01 May 2008
View article titled, Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission
Open the PDF for Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission in another window
Journal Articles

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Paul J. Sabbatini, Govind Ragupathi, Chandra Hood, Carol A. Aghajanian, Margrit Juretzka, Alexia Iasonos, Martee L. Hensley, Maria K. Spassova, Ouathek Ouerfelli, David R. Spriggs, William P. Tew, Jason Konner, Henrik Clausen, Nadeem Abu Rustum, Samuel J. Dansihefsky, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4170–4177.
https://doi.org/10.1158/1078-0432.CCR-06-2949
Published: 18 July 2007
View article titled, Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Open the PDF for Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in another window
Journal Articles

A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies

Carol Aghajanian, Steven Soignet, Don S. Dizon, Christine S. Pien, Julian Adams, Peter J. Elliott, Paul Sabbatini, Vincent Miller, Martee L. Hensley, Sandra Pezzulli, Christina Canales, Adil Daud, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2505–2511.
Published: 01 August 2002
View article titled, A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies
Open the PDF for A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies in another window